<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1817-5996</journal-id>
<journal-title><![CDATA[Revista Cubana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cuba Reumatol]]></abbrev-journal-title>
<issn>1817-5996</issn>
<publisher>
<publisher-name><![CDATA[Editorial CIMEQ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1817-59962018000300002</article-id>
<article-id pub-id-type="doi">10.5281/zenodo.1469019</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Validación de los expertos acerca de la conducta terapéutica a seguir con los pacientes con esclerosis sistémica]]></article-title>
<article-title xml:lang="en"><![CDATA[Experts' validation of therapeutic conduct for patients with systemic sclerosis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Remedios Batista]]></surname>
<given-names><![CDATA[Susel Elisabet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivas Carralero]]></surname>
<given-names><![CDATA[Raisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montada Cedeño]]></surname>
<given-names><![CDATA[Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[del Campo Avilés]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Pérez]]></surname>
<given-names><![CDATA[Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Holguín Hospital Clínico Quirúrgico Carlos Font Pupo ]]></institution>
<addr-line><![CDATA[Banes ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Pediátrico Octavio de la Concepción  ]]></institution>
<addr-line><![CDATA[Holguín ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Ciencias Médicas de Holguín Hospital Clínico Quirúrgico Lucía Iñiguez Landín ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>20</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1817-59962018000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1817-59962018000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1817-59962018000300002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Para la esclerosis sistémica no existe un tratamiento efectivo demostrado que modifique la enfermedad. El tratamiento de este padecimiento está encaminado a controlar los síntomas y signos, así como el daño orgánico con compuestos cuya acción tiene por objetivo prevenir o revertir la enfermedad como los que se administran en otras enfermedades reumáticas en dependencia de las manifestaciones en cada paciente. Para esta investigación se aplicó el método Delphi. Estudios realizados por investigadores de la Rand Corporation señalan que, si bien parece necesario contar con un mínimo de siete expertos, pues así el error disminuye notablemente por cada uno de ellos, no se aconseja más de 30. Esta investigación contó con 15 expertos. Desde el punto de vista científico, se obtiene una conducta terapéutica diferente desde las etapas tempranas del diagnóstico, en las cuales se les administra a los pacientes ciclofosfamida como inmunosupresor de primera elección. El procesamiento estadístico y la validación de la terapéutica mediante el método Delphi permitieron aplicar la conducta trazada para tratar a los enfermos desde los estadios clínicos iniciales. El objetivo de la investigación es validar la conducta terapéutica a seguir con los enfermos de esclerosis sistémica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT In the systemic sclerosis does not exist an effective therapy modifier of the confirmed disease. The treatment is centered on the control of symptoms and signs, as well as the organic commitment and not quite in a background processing whose action does not have for objective the control of the symptoms, but his prevention or reversion, as it has been utilized in another rheumatic diseases in dependence of the presentation in each patient. The method applied over himself Delphi, studies accomplished by the Rand's investigatorsCorporation, they indicate than even though a minimum of seven because the error decreases for each expert, to recur in addition to 30 it is not advisable, this investigation notably seems necessary required 15 experts. From the scientific point of view, a therapeutic different conduct from premature stages of the diagnosis is obtained, that the cyclophosphamide like inmunosoppressor of front line utilizes for affected patients. The statistical processing and the validation of the intervening therapeutics the method Delphi permitted the application of the conduct designed for the sick persons from clinical initial stadiums.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[esclerosis sistémica]]></kwd>
<kwd lng="es"><![CDATA[método Delfhi]]></kwd>
<kwd lng="es"><![CDATA[conducta terapéutica]]></kwd>
<kwd lng="en"><![CDATA[systemic sclerosis]]></kwd>
<kwd lng="en"><![CDATA[method Delfhi]]></kwd>
<kwd lng="en"><![CDATA[therapeutic conduct]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Expósito]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Concepción García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[El método Delphi para el procesamiento de los resultados de encuestas a expertos o usuarios en estudios de mercado y en la investigación educacional]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Holguín ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Holguín]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paneque]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Metodología de la investigación: elementos básicos para la investigación clínica]]></source>
<year>1998</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Valdés]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez Marín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El método Delphi para la consulta a expertos en la investigación científica]]></article-title>
<source><![CDATA[Revista Cubana de Salud Pública]]></source>
<year>2013</year>
<volume>39</volume>
<page-range>253-67</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trinchet Varela]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Trinchet Soler]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chacón Ronda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez Fals]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La experimentación paso final y determinante para validar el proceso de investigación científica en medicina]]></article-title>
<source><![CDATA[ACIMED]]></source>
<year>2008</year>
<volume>18</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Campos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are High Doses of Prednisone Necessary for Treatment of Interstitial Lung Disease in Systemic Sclerosis]]></article-title>
<collab>Estévez Del Toro M.Peña Casanovas A.Rojas G.Pablo P.Morales Sánchez L</collab>
<source><![CDATA[Reumatol Clin]]></source>
<year>2012</year>
<volume>8</volume>
<page-range>58-62</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Remedios Batista]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Velázquez Grass]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ciclofosfamida en el tratamiento de la esclerosis sistémica]]></article-title>
<collab>Del Campo Avilés E.Torres Pérez L.Fernández Portelles A</collab>
<source><![CDATA[Correo Científico Médico]]></source>
<year>2015</year>
<volume>19</volume>
<page-range>706-17</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Remedios Batista]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas Carralero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Jardinez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Alberteris Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Columbié]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto social de una conducta terapéutica diferente para la esclerosis sistémica]]></article-title>
<source><![CDATA[Correo Científico Médico]]></source>
<year>2017</year>
<volume>21</volume>
<page-range>219-35</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lepri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guiducci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bellando-Randone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Giani]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Blagojevic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS) report from a single VEDOSS/EUSTAR centre]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2015</year>
<volume>74</volume>
<page-range>124-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llerena]]></surname>
<given-names><![CDATA[GAR]]></given-names>
</name>
<name>
<surname><![CDATA[Toledano]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Solier]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mantecón]]></surname>
<given-names><![CDATA[AML]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreiro]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manifestaciones gastrointestinales severas en pacientes con Esclerosis Sistémica Progresiva Reporte de casos y revisión de la literatura]]></article-title>
<source><![CDATA[Revista Cubana de Reumatología]]></source>
<year>2007</year>
<volume>9</volume>
<page-range>22-30</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batista]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Elisabet]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas Carralero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Montada Cedeño]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia en pacientes con esclerosis sistémica en la provincia de Holguín]]></article-title>
<collab>del Campo Avilés E.Pérez Torres L</collab>
<source><![CDATA[Revista Cubana de Reumatología]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>65-72</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santosa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Teng]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Fong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[WG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort]]></article-title>
<source><![CDATA[Scandinavian Journal of Rheumatology]]></source>
<year>2016</year>
<volume>45</volume>
<page-range>499-506</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrisroe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Huq]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prior]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sahhar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ngian G-S]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Arthritis Research &amp; Therapy]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>122</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tashkin]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Volkmann]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Tseng C-H]]></surname>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Furst]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease Results of Scleroderma Lung Study II]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2017</year>
<volume>151</volume>
<page-range>813-20</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masui]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Asano]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shibata]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Akamata]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Aozasa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis]]></article-title>
<source><![CDATA[Mod Rheumatol]]></source>
<year>2013</year>
<volume>23</volume>
<page-range>323-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volkmann Elizabeth]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tashkin Donald]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Li Ning]]></surname>
</name>
<name>
<surname><![CDATA[Roth Michael]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna Dinesh]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MycophenolateMofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease An Analysis of Scleroderma Lung Studies I and II]]></article-title>
<collab>Hoffmann-Vold Anna-Maria</collab>
<source><![CDATA[Arthritis &amp; Rheumatology]]></source>
<year>2017</year>
<volume>69</volume>
<page-range>1451-60</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improvement of Severe Systemic Sclerosis-associated Gastric Antral Vascular Ectasia Following Immunosuppressive Treatment with Intravenous Cyclophosphamide]]></article-title>
<collab>O'brien M.Maqsood M.Sandorfi N.Galdo FD.Jimenez SA</collab>
<source><![CDATA[The Journal of Rheumatology]]></source>
<year>2009</year>
<volume>36</volume>
<page-range>1653-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pilar Simeon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[AngelPlasin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xaubet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fonollosa]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis]]></article-title>
<source><![CDATA[Archivos de Bronconeumología]]></source>
<year>2011</year>
<volume>47</volume>
<page-range>239-45</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Guiducci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bellando-Randone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bruni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lepri]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Czirják]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2014</year>
<volume>73</volume>
<page-range>2087-93</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tashkin]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Clements]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Furst]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kleerup]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial]]></article-title>
<source><![CDATA[Lancet Respir Med]]></source>
<year>2016</year>
<volume>4</volume>
<page-range>708-19</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
